COPD in a second level health care Institution in Bello, Antioquia, 2002-2007

Caracterización de la EPOC en una unidad de segundo nivel de atención en salud de Bello, Antioquia 2002-2007

Published 2008-06-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 20 No. 2 (2008)
Section
Research article
How to Cite
COPD in a second level health care Institution in Bello, Antioquia, 2002-2007.
rev. colomb. neumol. [Internet]. 2008 Jun. 1 [cited 2024 Nov. 24];20(2):38-44.
DOI
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Humberto Martínez Urrea
Médico Cardiólogo, Corporación Universitaria Remington. Medellín, Colombia
    Víctor Daniel Calvo Betancur
    Corporación Universitaria Remington, Sede Medellín. Medellín, Colombia.
      Martha Elena Bedoya Roldan
      Estudiante de Medicina, Corporación Universitaria Remington. Medellín, Colombia
        Vanessa Guarín Jaramillo
        Estudiante de Medicina, Corporación Universitaria Remington. Medellín, Colombia
          Show authors biography

          Humberto Martínez Urrea,

          Médico Cardiólogo, profesor titular Escuela de Ciencias de la Salud; Corporación Universitaria Remington. Medellín, Colombia

          Víctor Daniel Calvo Betancur,

          Profesor en Salud Pública, Facultad de Medicina, Corporación Universitaria Remington, Sede Medellín. Medellín, Colombia.

          Chronic Obstructive Pulmonary Disease (COPD) is a treatable and preventable disease, is featured by the airflow limitation not fully reversible.

          Objective: Compile information from COPD patients who attend to Rosalpi Hospital (Bello-Antoquia).

          Methods: It’s an epidemiological, observational, descriptive and retrospective trial, type cases series in 139 patients with COPD clinical criteria, registered in the clinical histories in a second level hospital between 2002-2007.

          Results: Clinical presentation for the patients accord to Anthonisen criteria was: 74.64% with dyspnea increase, 77.42% sputum production increase and 41.80% changes in sputum color. There weren’t statistically significant differences in age or sex at clinical presentation (p>0.05 respectively). Chronic bronchitis was present in 45.45% of the patients, emphysema 25.62% and mixed presentation 28.93%. During 2003-2004 there were statistically significant differences between tobacco exposure and exacerbations (p=0.049 and p=0.014 respectively).

          Conclusion: 42,86% COPD patients didn’t have tobacco exposure and 84.40% didn’t report smoke exposure from wood fires. This suggests that COPD in these patients arises from other factors, like air pollution or toxic contamination from their workplaces or homes.

          Article visits 47 | PDF visits 36

          Downloads

          Download data is not yet available.
          1. B.R. Celli, W. MacNee, A. Agusti, A. Anzueto, B. Berg, A.S. Buist, et al. Standard for the diagnosis and treatment of a patient with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946.
          2. Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J. Harrison’s Principles of Internal Medicine. 16th Edition. EEUU: McGraw-Hill; 2005.
          3. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
          4. Sobradillo V, Miravitlles M, Jimenez CA, Gabriel R, Viejo JL, Masa JF, et al. Estudio IBERCPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. Arch Bronconeumol 1999; 35: 159-66.
          5. World health report. Geneve: World Health Organization; 2000. Disponible en URL http://www.who.int/whr/2000/en/ statistics.htm
          6. Grupo de Neumología y Cirugía de tórax. Panorama epidemiológico e impacto económico actual. Rev Colomb Neumol; Vol. 66(S2): S13-S16, 2007.
          7. Organización Mundial de la Salud. Enfermedad pulmonar obstructiva crónica (EPOC). [Sitio en internet]. Disponible en: http://www.who.int/respiratory/copd/es/. Consulta: 22 de Octubre de 2007.
          8. Pérez-Padilla R, Epidemiología de EPOC en América Latina: proyecto PLATINO. ALAT, Santo Domingo, 2007.
          9. Caballero A, Torres C, Maldonado D, et. al. Prevalencia de la enfermedad pulmonar obstructiva crónica en Colombia (Prepocol). Asociación Colombiana de Neumología y Cirugía de Tórax, Fundación Neumológica Colombiana. 2005
          10. Sobradillo V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000;118:981-9
          11. Sociedad Chilena de Enfermedades Respiratorias. Guía Clínica Enfermedad Pulmonar Obstructiva Crónica: Chile está mejor, Reforma de la salud. Chile, 2006.
          12. Schirnhofer L, Lamprecht B, Vollmer WM, Allison MJ, StudnickaM, Jensen RL, Buist AS. COPD Prevalence in Salzburg, Austria: Results From the Burden of Obstructive Lung Disease (BOLD) Study. Chest 2007; 131:29-36.
          13. Air pollution and mortality: results from a study in Santiago, Chile. J Exp Environ Epidemiol 1996; 6: 97-114.
          14. The UCLA population studies of chronic obstructive respiratory diseases. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994; 149: 1209-17
          15. The relationship between pneumonia in early childhood and impaired lung function in late adult life. Am J Respir Crit care Med 1994; 149:616-9.
          16. Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Bronconeumol 2004; 40: 315 – 325.
          17. Colmenares Acero R. Exacerbación aguda de la enfermedad pulmonar obstructiva crónica – EPOC. [Sitio en internet]. Disponible en: http://www.fepafem.org.ve/guiaurgencias.php. Consulta: 25 de Noviembre de 2007.
          18. Doll H y Miravitlles M. La Calidad de Vida Relacionada con la Salud en Exacerbaciones Agudas de Bronquitis Crónica y Enfermedad Pulmonar Obstructiva Crónica. Pharmacoeconomics 2005; 23(4): 345-363.
          19. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
          20. Burge S, Wedzicha J A. COPD exacerbations: definitions and classifications. Eur Respir 2003; J 21 (Suppl 41): s46-s53.
          21. Voelkel N F, Rubin T. COPD: Exacerbation. Chest 2000; 117 (Suppl): 376s-39s.
          22. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations Chest 2000; 117:398S-401S.
          23. British Thoracic Society. COPD Guidelines Thorax 1997; (Suppl 5): S1-S32.
          24. Epidemiology of Chronic obstructive pulmonary disease exacerbations. C Pulm Med 2002; 9:191-7.
          25. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. On Behalf of the EOLO Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67: 495-501.
          26. Dewan NA, Rafique S, Kanwar B, Satpathy H, Ryschon K, Tillotson GS, et al. Acute exacerbation of COPD. Factors associated with poor outcome. Chest 2000; 117: 662-71.
          27. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-52.
          28. Grupo EPOC . Semi. Estudio de comorbilidad en pacientes EPOC atendidos en los servicios de medicina interna. Orihuela: Servicio de Medicina Interna. Hospital Vega Baja.
          29. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152 (suppl): S77-S120.
          30. Prevalence and risk factors for chronic bronchitis in Pelotas, RS, Brazil: a population-based study. Thorax 1994; 49:1217- 21.
          31. Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest 1999;116(2):416-23.
          32. Schermer TR, Jacobs JE, Chavannes NH, Hartman J, Folgering HT, Bottema BJ, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003;58(10):861-6.
          33. Schermer T, Eaton T, Pauwels R, van Weel C. Spirometry in primary care: is it good enough to face demands like World COPD Day? Eur Respir J 2003;22(5):725-7.
          34. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatador on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497- 505.
          35. Francisco O. Ramírez Duque. Guías de manejo de epoc. Metrosalud. Medellín; 2007.
          36. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143(5):317-26.
          37. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005;127(3):809-17.
          38. Sociedad colombiana de neumología y cirugía de tórax. Recomendaciones para el diagnóstico y el manejo del paciente con enfermedad pulmonar obstructiva crónica (EPOC). Rev Colomb Neumol 1997; suplemento volumen 9 diciembre.
          39. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-5.
          40. Tarpy S.P, Celli B.R. Long-Term oxygen therapy. N Engl J Med 1995; 333(11): 710-4.
          41. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93(3):391-8.

          Information

          Journal history

          Keywords

          QR code

          Funding

          Support + Info: Here

           

           

          Directories and indexes

          Google Scholar profile

          Most read in the last 30 days

          Current Issue

          Sistema OJS 3.4.0.7 - Metabiblioteca |